We are a blank check company. e may pursue an initial business combination in any business or industry but expect to focus on a target in industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare related industries and, in particular, life sciences, globally. We intend to prioritize companies in the life sciences sector where our management team has extensive experience. Joining our company is a team of high-level senior life sciences executives. The team includes Ryan Gilbert, who will serve as our Chairman of the Board upon the commencement of trading of our units on Nasdaq, Chris Ehrlich, our Chief Executive Officer, and Jurgen van de Vyver, our Chief Financial Officer. Our Board of Directors is expected to provide valuable guidance, technical domain expertise, value-added input regarding senior team leadership capabilities of prospective business combination targets, and have access to differentiated ideas and opportunities through complementary networks. They also have specific special purpose acquisition company, or SPAC, experience and a proven track record of business combination success.